Mavissakalian M, Perel J
Am J Psychiatry. 1985 Sep;142(9):1032-6. doi: 10.1176/ajp.142.9.1032.
The authors examined dose-response relationships in 62 agoraphobic patients receiving either imipramine or placebo under double-blind conditions in conjunction with behavioral interventions. At the end of 12 weeks, patients treated with imipramine had improved significantly more than placebo patients. Results revealed that the beneficial therapeutic effect of imipramine was dose dependent and suggested that optimal response in agoraphobia may require doses of 150 mg/day or more. The results also indicated that side effects can significantly interfere with the buildup of optimal dose in agoraphobic patients treated with imipramine. The authors briefly discuss the implications of these findings for clinical practice and future research.
作者对62名广场恐惧症患者进行了剂量反应关系研究，这些患者在双盲条件下接受丙咪嗪或安慰剂治疗，并结合行为干预措施。12周结束时，接受丙咪嗪治疗的患者比接受安慰剂治疗的患者改善明显更多。结果显示，丙咪嗪的有益治疗效果呈剂量依赖性，提示广场恐惧症的最佳反应可能需要150毫克/天或更高的剂量。结果还表明，副作用会显著干扰接受丙咪嗪治疗的广场恐惧症患者达到最佳剂量的过程。作者简要讨论了这些发现对临床实践和未来研究的意义。
